




Figure S1. Patient flow.  
 
 
Figure S2.  Cardiovascular death (A-C) and MACE* (D-E) in patients with acute heart failure in the presence of relative hypochromia 
 
720-day cardiovascular death in patients stratified according to hypochromia (MCHC≤330g/l) vs. non-hypochromia in the overall AHF cohort (A), in anemic 
AHF patients according to hypochromia (B), and in non-anemic AHF patients according to hypochromia (C). 720-day mortality due to MACE in patients 
stratified according to hypochromia (MCHC≤330g/l) vs. non-hypochromia in the overall AHF cohort (D), in anemic AHF patients (E) and in non-anemic 
AHF patients (F) according to hypochromia.   
 
* the composite of cardiovascular mortality, admission for AHF or other cardiovascular events 
 
AHF: Acute heart failure. MACE: Major adverse cardiovascular events.  




AHF: Acute heart failure. MCHC: mean corpuscular hemoglobin concentration.  
Figure S3. Time dependent ROC curves describing the prognostic performance of the MEESSI AHF risk score and its combination with MCHC to 











Table S1A: Characteristics of anemic patients (n=712) with acute heart failure (AHF) according to the 
presence of relative hypochromia 
Abbreviations: 
ARBs: Angiotensin II Receptor Blockers; ASS: acetylsalicylic acid; AT: Aldosterone-receptor antagonists; BMI: Body mass index; CKD-
Epi: Chronic Kidney Disease Epidemiology Collaboration; eGFR: estimated glomerular filtration rate calculated according to CKD-EPI; 
CCB: Calcium Channel Blocker; BNP: B-type brain natriuretic peptide; COPD: Chronic obstructive pulmonary disease; CRP: C-reactive 
protein, dBP: diastolic blood pressure; HR: heart rate; LV: left ventricular; MCHC: mean corpuscular hemoglobin concentration; MCH: 
mean corpuscular hemoglobin; NT-proBNP: N-terminal pro-B-type natriuretic peptide; sBP: systolic blood pressure; hs-TnT: high 
sensitive Troponin T. 





Variables   p-value 
Demographics    
    Age (years) 80 (72-85) 80 (73-85) 0.509 
    Female (%) 44 35 0.015 
    Weight (kg) 73 (62-87) 74 (64-83) 0.933 
    BMI (kg/m2) 26 (23-30) 26 (23-29) 0.352 
    
Medical history    
    Coronary Artery Disease (%) 66 61 0.179 
    Hypertension (%) 86 83 0.301 
    Peripheral artery disease (%) 23 21 0.496 
    Stroke (%) 19 21 0.413 
    Dyslipidemia (%) 62 61 0.965 
    Diabetes (%) 39 37 0.661 
    Current or ex-smoker (%) 66 59 0.058 
    Chronic kidney disease (%) 64 59 0.180 
    COPD (%) 32 21 0.002 
    Active malignancies (%) 2 1 0.593 
AHF precipitating conditions    
    Worsening Heart Failure          66 66 0.972 
    Infection 17 25 0.012 
    Cardiogenic shock 2 1 0.593 
Laboratory data    
    Hemoglobin (g/l) 108 (94-116) 113 (105-120) <0.001 
    Hematocrit (%) 34 (29-36) 33 (31-35) 0.300 
    MCHC (g/l) 322 (316-326) 341 (335-347) <0.001 
    MCH (pg) 28 (26-30) 31 (29-32) <0.001 
    Creatinine (µmol/l) 131 (92-179) 119 (89-172) 0.239 
    Urea (mmol/l) 13 (9-19) 11 (7-17) 0.002 
    eGFR (ml/min/1.73m2) 40 (27-60) 45 (29-64) 0.093 
    Albumin (g/l) 33 (31-36) 34 (31-36) 0.627 
    CRP (mg/l) 16 (6-35) 16 (5-43) 0.952 
    Sodium (mmol/l) 139 (137-142) 138 (135-141) <0.001 
    Potassium (mmol/l) 4.3 (3.9-4.7) 4.2 (3.9-4.6) 0.114 
    
Clinical parameters     
    sBP (mmHg) 131 (117-148) 130 (117-157) 0.053 
    dBP (mmHg) 73 (62-83) 75 (63-89) 0.069 
    HR (beats/min) 82 (69-102) 83 (70-99) 0.069 
    LV ejection fraction (%) 45 (30-55) 45 (32-57) 0.400 
    Atrial fibrillation (%) 48 42 0.135 
    
Cardiac biomarker    
    NT-proBNP (ng/l) 6351 (3449-12429) 5849 (2521-12309) 0.091 
    hs-TnT(ng/l) 47 (30-61) 40 (25-81) 0.085 
    
Medication at admission    
    ACE inhibitors (%) 45 45 0.948 
    ARBs (%) 27 26 0.744 
    CCB (%) 25 31 0.085 
    Beta blockers (%) 59 63 0.317 
    Diuretics (%) 82 74 0.017 
    Aldosterone-receptor      







    ASS (%) 43 47 0.320 




Table S1B: Characteristics of non-anemic acute heart failure (AHF) patients according to the presence of 
relative hypochromia (n=861) 
 
Abbreviations: 
ARBs: Angiotensin II Receptor Blockers; BMI: Body mass index; CKD-Epi: Chronic Kidney Disease Epidemiology 
Collaboration; eGFR: estimated glomerular filtration rate calculated according to CKD-EPI; CCB: Calcium Channel 
Blocker; BNP: B-type brain natriuretic peptide; CRP: C-reactive protein, dBP: diastolic blood pressure; HR: heart rate; 
LV: left ventricular; MCHC: mean corpuscular hemoglobin concentration; MCH: mean corpuscular hemoglobin, NT-
proBNP: N-terminal pro-B-type natriuretic peptide; sBP: systolic blood pressure; hs-TnT: high sensitive Troponin T. 
 
 No anemia with 
hypochromia (n=158) 
No anemia without 
hypochromia (n=703) 
 
Variables   p-value 
Demographics    
    Age (years) 77 (69-84) 78 (68-85) 0.486 
    Female, %) 47 45 0.715 
    Weight (kg) 74 (63-85) 75 (64-88) 0.217 
    BMI (kg/m2) 26 (23-29) 26 (23-30) 0.190 
    
Medical history    
    Coronary Artery Disease (%) 54 44 0.027 
    Hypertension (%) 65 77 0.002 
    Peripheral artery disease (%) 14 15 0.605 
    Stroke (%) 15 15 0.849 
    Dyslipidemia (%) 51 48 0.537 
    Diabetes (%) 28 23 0.131 
    Current or ex-smoker (%) 61 64 0.504 
    Chronic kidney disease (%) 41 32 0.030 
    COPD (%) 32 24 0.042 
    Malignancies (%)    
       
Laboratory data    
    Hemoglobin (g/l) 139 (130-150) 140 (132-151) 0.252 
    Hematocrit (%) 43 (40-47) 40 (38-44) <0.001 
    MCHC (g/l) 325 (320-328) 343 (338-351) <0.001 
    MCH (pg) 30 (28-31) 31 (30-32) <0.001 
    Creatinine (µmol/l) 106 (81-142) 94 (75-124) 0.002 
    Urea (mmol/l) 10 (7-15) 8 (6-11) <0.001 
    eGFR (ml/min/1.73m2) 51 (36-74) 59 (42-78) 0.004 
    Albumin (g/l) 35 (32-38) 36 (33-38) 0.443 
    CRP (mg/l) 9 (4-24) 8 (3-27) 0.602 
    Sodium (mmol/l) 139 (137-141) 139 (136-141) 0.102 
    Potassium (mmol/l) 4.3 (3.9-4.8) 4.1 (3.8-4.3) <0.001 
    
Clinical parameters     
    sBP (mmHg) 135 (119-159) 140 (122-159) 0.159 
    dBP (mmHg) 86 (76-95) 83 (71-97) 0.289 
    HR (beats/min) 100 (85-114) 90 (76-110) 0.006 
    LV ejection fraction (%) 40 (25- 56) 45 (30- 57) 0.117 
    Atrial fibriliation (%) 47 44 0.508 
    
Cardiac biomarker    
    NT-proBNP (ng/l) 5354 (2781-10128) 3943 (1812-7766) 0.001 
    hs-TnT(ng/l) 33 (20-65) 33 (18-58) 0.209 
    
Medication at admission    
    ACE inhibitors (%) 40 40 0.883 
    ARBs (%) 16 23 0.070 
    CCB (%) 9 19 0.003 
    Beta blockers (%) 59 57 0.592 
    Diuretics (%) 67 63 0.356 
    Aldosterone-receptor      
    Antagonists (%) 
15 11 0.196 
 
 
Table S2: Multivariable Cox proportional hazards model for all-cause mortality, cardiovascular death and 
combined endpoint of all-cause mortality or AHF-related hospitalizations with MCHC≤335 
 
 
Abbreviations: AHF: acute heart failure, BMI: Body mass index; NT-proBNP: N-terminal pro-B-type 
natriuretic peptide, CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; eGFR: estimated 
glomerular filtration rate calculated according to CKD-EPI, LV = left ventricle; MCHC: mean 
























 Hazard ratio p-value 95% CI 
All-cause mortality    
  Age (years) 1.033 <0.001 1.019-1.048 
  Sex 0.682 0.001 0.539-0.862 
  BMI 0.956 <0.001 0.932-0.980 
  eGFR (ml/min/1.73m2) 0.987 <0.001 0.982-0.993 
  Hemoglobin at admission (g/l) 1.000 0.884 0.995-1.006 
  MCHC≤335 (g/l) 1.571 <0.001 1.251-1.974 
  lg NT-proBNP (ng/l) 2.073 <0.001 1.489-2.884 
  LV Ejection Fraction (%) 1.003 0.431 0.955-1.011 
Cardiovascular death    
  Age (years) 1.020 0.001 1.011-1.046 
 Sex 0.757 0.063 0.564-1.015 
  BMI 0.955 0.004 0.925-0.985 
  eGFR (ml/min/1.73m2) 0.983 <0.001 0.976-0.991 
  Hemoglobin at admission (g/l) 1.000 0.937 0.993-1.008 
  MCHC≤335 (g/l) 1.562 0.002 1.173-2.078 
  lg NT-proBNP (ng/l) 1.986 0.001 1.304-3.025 
  LV Ejection Fraction (%) 0.993 0.191 0.983-1.003 
All-cause mortality & AHF rehospitalization 
  Age (years) 1.017 0.006 1.005-1.029 
  Sex 0.793 0.023 0.642-0.981 
  BMI 0.975 0.022 0.954-0.996 
  eGFR (ml/min/1.73m2) 0.990 <0.001 0.985-0.955 
  Hemoglobin at admission (g/l) 1.001 0.746 0.996-1.006 
  MCHC≤335 (g/l) 1.538 <0.001 1.251-1.892 
  lg NT-proBNP (ng/l) 1.902 <0.001 1.413-2.561 





Table S3: Patients with AHF (n=1574) stratified by heart failure phenotypes, precipitating and predisposing 
conditions and corresponding MCHC levels.   
 
AHF phenotypes  Yes No p-value 
Hypertensive heart failure      n (%) 141 (9) 1433 (91)  
 MCHC (g/l) 341 (332-349) 337 (328-346) 0.004 
Worsening heart failure        n (%) 1008 (64) 566 (36)  
 MCHC (g/l) 338 (329-346) 338 (328-346) 0.366  
Pulmonary edema n (%) 39 (2) 1535 (98)  
 MCHC (g/l) 334 (324-340) 338 (329-346) 0.014 
Right heart failure n (%) 33 (2) 1541(98)  
 MCHC (g/l) 337 (324-347) 338 (329-346) 0.559 
Cardiogenic shock n (%) 16 (19) 2826 (99)  
 MCHC (g/l) 335 (321-346) 341 (332-350) 0.192 
AHF precipitating conditions    
ACS n (%) 86 (5) 1488 (95)  
 MCHC (g/l) 341 (330-349) 337 (329-346) 0.027 
Arrhythmia n (%) 392 (25) 1282 (75)  
 MCHC (g/l) 339 (329-347) 337 (329-346) 0.288 
Infection n (%) 324 (21) 1250 (79)  
 MCHC (g/l) 340 (330-348) 337 (328-340) 0.019 
Predisposing factors for AHF    
Post-MI n (%) 125 (9) 1449 (92)  
 MCHC (g/l) 336 (324-346) 338 (329-346) 0.357 
Rhythmogenic AHF 
(chronic arrhythmia) 
n (%) 179 (11) 1395 (89)  
 MCHC (g/l) 340 (331-348) 338 (328-346) 0.036 
Rhythmogenic AHF 
(chronic Afib only) 
n (%) 160 (10) 1414 (90)  
 MCHC (g/l) 339 (331-348) 338 (328-346) 0.089 
Cardiomyopathy n (%) 75 (5) 1499 (95)  
 MCHC (g/l) 338 (330-348) 338 (329-346) 0.418 
Pulmonary hypertension n (%) 122 (8) 1452 (92)  
 MCHC (g/l) 335 (324-344) 338 (329-346) 0.046 
Vital Signs at Presentation    
SpO2 n (%) 312 (22) 1197 (78)  
 MCHC (g/l) 336 (326-346) 338 (330-347) 0.058 
RR<90syst. n (%) 31 (2) 1509 (98)  
 MCHC (g/l) 337 (328-342) 338 (329-346) 0.332 










Table S4: Multivariable Cox proportional hazards model for all-cause mortality in AHF patients with 
arrhythmias and ACS.  
 
* Interaction p-values between Hypochromia and AHF precipitating conditions: 0.281 for arrhythmia 
and AHF; 0.151 for ACS and AHF. 
 
Abbreviations: ACS: acute coronary syndrome; AHF: acute heart failure; MI: myocardial infarction, 
NT-proBNP: N-terminal pro-B-type natriuretic peptide 
 
 
Table S5: Interaction of Hypochromia with different AHF phenotypes and precipitating factors for 
predicting all-cause mortality at 720 days. 
 
 interaction p-value 
AHF phenotypes  
Hypertensive Heart Failure      0.529 
Worsening Heart Failure        0.837 
Pulmonary Edema 0.269 
Right Heart Failure 0.015 
Cardiogenic shock 0.469 





Table S6: Interaction of Hypochromia with different AHF phenotypes and precipitating factors for 
predicting all-cause mortality or AHF rehospitalizations at 720 days. 
 
 interaction p-value 
AHF phenotypes  
Hypertensive Heart Failure      0.319 
Worsening Heart Failure        0.701 
Pulmonary Edema 0.147 
Right Heart Failure 0.013 
Cardiogenic shock 0.718 





Abbreviations: ACS: acute coronary syndrome; AHF: acute heart failure.  
 Hazard ratio p-value 95% CI 
All-cause mortality    
  Arrhythmia* 0.637 0.001 0.486- 0.834 
  ACS* 1.193 0.400 0.791- 1.798 
  Age (years) 1.034 <0.001 1.020- 1.048 
  Sex 0.725 0.007 0.573- 0.918 
  BMI 0.958 0.001 0.934- 0.982 
  eGFR (ml/min/1.73m2) 0.987 <0.001 0.981-0.993 
  Hemoglobin at admission (g/l) 1.002 0.586 0.996-1.008 
  Hypochromia (yes/no)* 1.528 <0.001 1.207-1.935 
  lg NT-proBNP (ng/l) 2.028 <0.001 1.461-2.815 




Table S7. Risk factors for the MEESSI AHF risk score. 
 
Risk factors  




Elevated troponin level 




Episode associated with ACS 
Hypertrophy on ECG 
Creatinine plasma concentration 
 
Abbreviations: ACS: acute coronary syndrome; AHF: acute heart failure; NT-proBNP: N-terminal pro-B-
type natriuretic peptide
  
Table S8. MEESSI AHF risk score reclassification by means of MCHC 
 
Alive at 720 days 
 
 MCHC and MEESSI AHF risk score 
MEESSI AHF risk score 0-0.1 0.1-0.2 0.2-0.3 0.3-0.4 0.4-0.5 0.5-0.6 0.6-0.7 0.7-0.8 0.8-0.9 0.9-1.0 % reclassified 
0- 0.1 7 0 0 0 0 0 0 0 0 0 0 
0.1-0.2 69 15 0 0 0 0 0 0 0 0 82 
0.2-0.3 0 209 49 0 0 0 0 0 0 0 81 
0.3-0.4 0 0 0 177 63 0 0 0 0 0 26 
0.4-0.5 0 0 0 0 0 0 0 0 0 0 - 
0.5-0.6 0 0 0 0 0 69 25 0 0 0 27 
0.6-0.7 0 0 0 0 0 0 0 0 0 0 - 
0.7-0.8 0 0 0 0 0 0 16 12 0 0 57 
0.8-0.9 0 0 0 0 0 0 0 0 2 0 0 
0.9-1.0 0 0 0 0 0 0 0 0 0 0 - 
 
Dead at 720 days 
 
 MCHC and MEESSI AHF risk score 
MEESSI AHF risk score 0-0.1 0.1-0.2 0.2-0.3 0.3-0.4 0.4-0.5 0.5-0.6 0.6-0.7 0.7-0.8 0.8-0.9 0.9-1.0 % reclassified 
0-0.1 0 0 0 0 0 0 0 0 0 0 - 
0.1-0.2 7 2 0 0 0 0 0 0 0 0 78 
0.2-0.3 0 44 27 0 0 0 0 0 0 0 62 
0.3-0.4 0 0 0 91 52 0 0 0 0 0 36 
0.4-0.5 0 0 0 0 0 0 0 0 0 0 - 
0.5-0.6 0 0 0 0 80 48 0 0 0 0 38 
0.6-0.7 0 0 0 0 0 0 0 0 0 0 - 
0.7-0.8 0 0 0 0 0 0 35 27 0 0 56 
0.8-0.9 0 0 0 0 0 0 0 0 16 0 0 






 MEESSI AHF risk score 
MEESSI AHF risk score 0-0.1 0.1-0.2 0.2-0.3 0.3-0.4 0.4-0.5 0.5-0.6 0.6-0.7 0.7-0.8 0.8-0.9 0.9-1.0 % reclassified 
0-0.1 0 0 0 0 0 0 0 0 0 0 0 
0.1-0.2 76 17 0 0 0 0 0 0 0 0 82 
0.2-0.3 0 253 76 0 0 0 0 0 0 0 77 
0.3-0.4 0 0 0 268 115 0 0 0 0 0 30 
0.4-0.5 0 0 0 0 0 0 0 0 0 0 - 
0.5-0.6 0 0 0 0 0 149 73 0 0 0 33 
0.6-0.7 0 0 0 0 0 0 0 0 0 0 - 
0.7-0.8 0 0 0 0 0 0 51 39 0 0 57 
0.8-0.9 0 0 0 0 0 0 0 0 18 0 0 
0.9-1.0 0 0 0 0 0 0 0 0 0 3 0 
 
NRI (categorical) (95% CI): 0.321 (0.242-0.400); p<0.001 
NRI (continuous) (95% CI): 0.279 (0.169-0.390); p<0.001 
IDI (95% CI): 0.011 (0.004-0.017); p<0.001 
 
IDI: Integrated discrimination index. NRI: Net reclassification improvement. 
  
Supplementary Table S9.  Spearman`s rank correlation analysis between Hypochromia and 
demographics, biomarkers and echo parameters. Correlation was calculated with measurements 






























LA: Left atrium. LVEDD: Left ventricular end diastolic diameter. LVEF: Left ventricular ejection 




  MCHC 
Albumin Spearman`s rank (rs) 0.136 
 p-value <0.001 
GFR Spearman`s rank (rs) -0.206 
  p-value <0.001 
Potassium Spearman`s rank (rs) -0.207 
  p-value <0.001 
Sodium Spearman`s rank (rs) -0.118 
  p-value <0.001 
LA diameter (mm) Spearman`s rank (rs)  0.134 
  p-value <0.001 
LVEF (%) Spearman`s rank (rs) 0.079 
  p-value 0.008 
LVEDD (%) Spearman`s rank (rs) -0.043 
  p-value 0.183 
LVESD (%) Spearman`s rank (rs) -0.026 
  p-value 0.468 
Septum (mm) Spearman`s rank (rs) 0.029 
 p-value 0.416 
Posterior wall (mm) Spearman`s rank (rs) -0.021 
  p-value 0.559 
